Millions of People Will Soon Be Blindsided. Will You Be One of Them?

On April 20 at 7 p.m. ET, Louis Navellier and Matt McCall will reveal an event that’s about to rock the stock market and how you could use it to beat the markets by nearly 11X.

Tue, April 20 at 7:00PM ET
 
 
 
 

17 Biotechnology Stocks to Buy Now

17 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Regeneron Pharmaceuticals, Inc.’s (REGN) ratings are looking better this week, moving up to a A from last week’s B. Regeneron Pharmaceuticals, Inc. researches, develops and commercializes therapeutics to treat human disorders and conditions. The company also gets A’s in sales growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of REGN stock.

United Therapeutics Corporation (UTHR) earns a B this week, jumping up from last week’s grade of C. United Therapeutics Corporation is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. The company also gets A’s in operating margin growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of UTHR stock.

This week, Vertex Pharmaceuticals Incorporated’s (VRTX) ratings are up from a C last week to a B. Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VRTX stock.

BioSpecifics Technologies Corp. (BSTC) improves from a B to a A rating this week. BioSpecifics Technologies Corp. is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. The company also gets A’s in sales growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of BSTC stock.

This is a strong week for SAGE Therapeutics, Inc. (SAGE). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of SAGE stock.

Isis Pharmaceuticals, Inc. (ISIS) shows solid improvement this week. The company’s rating rises from a C to a B. Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ISIS stock.

This week, Chimerix, Inc. (CMRX) pushes up from a C to a B rating. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of CMRX stock.

Newlink Genetics Corporation (NLNK) is seeing ratings go up from a C last week to a B this week. Newlink Genetics Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The company also gets A’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NLNK stock.

ACADIA Pharmaceuticals Inc. (ACAD) boosts its rating from a C to a B this week. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. For more information, get Portfolio Grader’s complete analysis of ACAD stock.

Dyax Corp. (DYAX) gets a higher grade this week, advancing from a B last week to a A. Dyax Corp. is engaged in the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of DYAX stock.

The rating of Sarepta Therapeutics, Inc. (SRPT) moves up this week, rising from a C to a B. Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. For more information, get Portfolio Grader’s complete analysis of SRPT stock.

Enzymotec Ltd. (ENZY) improves from a B to a A rating this week. The company also gets A’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

This week, Cytokinetics, Incorporated’s (CYTK) ratings are up from a B last week to a A. Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CYTK stock.

Strongbridge Biopharma plc (SBBP) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of SBBP stock.

Calithera Biosciences, Inc. (CALA) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of CALA stock.

This is a strong week for Amicus Therapeutics, Inc. (FOLD). The company’s rating climbs to B from the previous week’s C. Amicus Therapeutics, Inc. is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. For more information, get Portfolio Grader’s complete analysis of FOLD stock.

This week, Aldeyra Therapeutics, Inc. (ALDX) pushes up from a C to a B rating. The company also gets A’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/11/17-biotechnology-stocks-to-buy-now/.

©2021 InvestorPlace Media, LLC